Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of a Reduced-toxicity Myeloablative Conditionning Regimen Using Fludarabine and Full Doses of iv Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens

NCT01572181 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT01572181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01572181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of a Reduced-toxicity Myeloablative Conditionning Regimen Using Fludarabine and Full Doses of iv Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens
Lead sponsor
Nantes University Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2012
Completion date
October 24, 2017
Enrollment
50 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancy